Vaxil Bio Ltd. is an immunotherapy biotech company, which is engaged in the development of immunotherapies such as neoantigen-like peptide products, and antibodies to treat cancer and infectious diseases. The firm's pipeline consists of ImMucin, SPmAb2, SPmAb6, and MTbuVax. The company was founded on July 26, 2006 and is headquartered in Toronto, Canada.
CEO： Dr. Yuval Avnir
Market： Pink Market